qy201
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2022 (NCT05525715)
Timeline
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07180511 | Phase 3 | Mar 12, 2025 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. |
| NCT05525715 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2022 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Zhejiang University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1